Sitagliptin: anti-platelet effect in diabetes and healthy volunteers. - Wikidata - awgldk - TriplyDB

Sitagliptin: anti-platelet effect in diabetes and healthy volunteers.

Sitagliptin: anti-platelet effect in diabetes and healthy volunteers.

http://www.wikidata.org/entity/Q51313041

about

Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial Glucagon-like peptide-1 receptor signalling reduces microvascular thrombosis, nitro-oxidative stress and platelet activation in endotoxaemic mice.The nonglycemic actions of dipeptidyl peptidase-4 inhibitors Anti-atherosclerotic effects of sitagliptin in patients with type 2 diabetes mellitus.Cardiovascular effects of gliptins.Dipeptidyl peptidase-4 inhibitors: multitarget drugs, not only antidiabetes drugs.Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.Dipeptidyl peptidase-4 inhibitors and their effects on the cardiovascular system.Potential anti-atherosclerotic effects of dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus.Antiatherothrombotic effects of dipeptidyl peptidase inhibitors.Potential impact of dipeptidyl peptidase-4 inhibitors on cardiovascular pathophysiology in type 2 diabetes mellitus.DPP-4 inhibitors: a patent review (2012 - 2014).Dipeptidyl Peptidase-4 Inhibitor-Associated Risk of Bleeding: An Evaluation of Reported Adverse Events.Effects of teneligliptin on PDMPs and PAI-1 in patients with diabetes on hemodialysis.Platelets and diabetes: a complex association.

P2860

Q31155491-E1ADFB50-3388-4911-996E-E21AFD5361C8 Q33434017-B7267180-8DC2-4E5C-AE52-445AD134B50C Q34029715-3F5237BF-1545-48DB-8877-C0BF50B334AF Q35914764-ABF6A11B-A97F-47EE-8A70-70652F204C0F Q38072259-45A706DB-0810-4137-99B6-BB74986B3FB7 Q38107546-010A757E-0DA1-42CE-992C-455755A12018 Q38113092-2C262B9B-DFFD-4FD8-AB57-75C61517E57E Q38118157-29553383-1AB9-47F8-99B8-F97E295D88AD Q38175855-E9FA4141-9D08-4578-9AF1-E35B3560C830 Q38195527-83827A39-8411-4F4E-AF05-B27528347A51 Q38219481-8DD1B8A3-BE51-4844-9736-8F44EDAA73DD Q38284522-0DECC2CC-D655-45BC-88EC-154C48A25E01 Q38976138-6CDE4CD7-270C-4FC8-9338-EA9AEA7C4DDE Q40294653-1C78940F-9CBE-4A4D-8BB8-E6BC7B7C9B87 Q53130761-1354F0AB-C004-46D6-BC8B-86AFAEA9CA24

P2860

Sitagliptin: anti-platelet effect in diabetes and healthy volunteers.

http://www.wikidata.org/entity/Q51313041

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh-hant

name

Sitagliptin: anti-platelet effect in diabetes and healthy volunteers.

@en

Sitagliptin: anti-platelet effect in diabetes and healthy volunteers.

@nl

type

label

Sitagliptin: anti-platelet effect in diabetes and healthy volunteers.

@en

Sitagliptin: anti-platelet effect in diabetes and healthy volunteers.

@nl

prefLabel

Sitagliptin: anti-platelet effect in diabetes and healthy volunteers.

@en

Sitagliptin: anti-platelet effect in diabetes and healthy volunteers.

@nl

P1433

Q51313041-9FBE911E-ACC6-4B68-AA43-9DC9BC382BC9

P1476

Q51313041-F1F30CA6-EAD4-45BE-9888-95C6409E4811

P2093

Q51313041-08A314C6-63DD-476B-9D57-B62BE8C78A2F

Q51313041-13074B86-36D0-498C-BCE8-243B87D647B9

Q51313041-36588508-217E-41B9-98D9-F993EC2E89A6

Q51313041-A1E205E1-707B-40A7-8CD7-240A6DAD8BFD

Q51313041-C3937876-E3B3-4795-B101-F627FCBAFAED

P2860

Q51313041-0B76A2B8-58E7-4F4E-AC74-6A8413DE006C

Q51313041-1140DD51-0D94-4A4D-B6DE-2DD1670E609F

Q51313041-183B2AEB-88F7-495A-996D-72C7F683E6A2

Q51313041-194CA5E5-43D7-4197-99BA-506D15E68507

Q51313041-2CE29A1B-31ED-48A5-B04B-81CC2D6747F0

Q51313041-35533612-75F8-44E1-95A4-E4D5E7EA5A24

Q51313041-40CFFC28-6E8A-492B-8E66-C987FF53EC41

Q51313041-47B8681F-A2EA-43DA-8EFB-F34172949622

Q51313041-4BE8B13C-AC0D-494A-8BF9-5411A21B5ACB

Q51313041-7D00373D-BE66-4685-B281-B503F55FAF0C

P304

Q51313041-5A64B912-8C27-4FA1-B467-C925D96ACA3B

P31

Q51313041-E527918A-B3FF-4FC7-8D69-3D5C54D6583D

P356

Q51313041-08B31970-792C-46AE-A65A-9F99692CD317

P433

Q51313041-8D729FDE-A4F0-4F0A-9F85-1C0195D43E59

P478

Q51313041-56C4CA36-729D-48B7-9A98-487B0E580084

P577

Q51313041-7C9E121C-D5CC-41D7-85C8-DC40F85C91AC

P5875

Q51313041-B631CACF-A9FA-4C29-923D-12B2E902C176

P698

Q51313041-20A01F0E-A302-47E2-9721-60BBBCE04F2A

P356

09537104.2012.721907

P1433

P1476

Sitagliptin: anti-platelet effect in diabetes and healthy volunteers.

@en

P2093

Akhilesh Kumar Verma

http://www.w3.org/2001/XMLSchema#string

Ashish Kumar Gupta

http://www.w3.org/2001/XMLSchema#string

Jyotsna Kailashiya

http://www.w3.org/2001/XMLSchema#string

Narender Kumar

http://www.w3.org/2001/XMLSchema#string

Surya Kumar Singh

http://www.w3.org/2001/XMLSchema#string

P2860

Ca2+ and pH determine the interaction of chromaffin cell scinderin with phosphatidylserine and phosphatidylinositol 4,5,-biphosphate and its cellular distribution during nicotinic-receptor stimulation and protein kinase C activation

Platelet aggregation inhibition with glycoprotein IIb--IIIa inhibitors.

Intracellular pH in human and experimental hypertension

Platelet function in patients with diabetes mellitus: from a theoretical to a practical perspective

Signaling events underlying thrombus formation.

Tyrosine phosphorylated c-Cbl regulates platelet functional responses mediated by outside-in signaling

GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes.

Oncocalyxone A inhibits human platelet aggregation by increasing cGMP and by binding to GP Ibalpha glycoprotein

Inhibition of calpain blocks platelet secretion, aggregation, and spreading

Intensive glucose-lowering therapy reduces cardiovascular disease events in veterans affairs diabetes trial participants with lower calcified coronary atherosclerosis.

P304

565-570

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/09537104.2012.721907

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P577

2012-09-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230803498

http://www.w3.org/2001/XMLSchema#string

P698

22950787

http://www.w3.org/2001/XMLSchema#string